A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

Jon B. Bishop, Linda Phillips, Thomas A. Mustoe, A. John VanderZee, Laurel Wiersema, Dell E. Roach, John P. Heggers, Donald P. Hill, Eugene L. Taylor, Martin C. Robson

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Chronic wounds such as venous stasis ulcers have become a socioeconomic problem. Even with successful initial management, the recurrence rate approaches 70%. With the advent of new wound healing agents, nonoperative attempts to heal these wounds appear indicated. This study reports a prospective randomized evaluator-blinded trial comparing two potential wound healing agents to an inert vehicle placebo. Eighty-six evaluable patients completed the trial. Silver sulfadiazine 1% in a cream proved to statistically reduce the ulcer size compared with a biologically active tripeptide copper complex 0.4% cream formulation or the placebo. There was no difference between the latter two treatments. Silver sulfadiazine has been shown to allow keratinocyte replication and to have antiinflammatory properties. In this trial its antibacterial action was not used since all ulcers had comparable bacterial levels (≤ 105/gm of tissue) before treatment. These results suggest that the silver sulfadiazine cream used in this study may facilitate healing in wounds healing largely by the process of epithelization.

Original languageEnglish (US)
Pages (from-to)251-257
Number of pages7
JournalJournal of Vascular Surgery
Volume16
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Silver Sulfadiazine
Varicose Ulcer
Wound Healing
Ulcer
Placebos
Wounds and Injuries
Keratinocytes
Copper
Anti-Inflammatory Agents
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. / Bishop, Jon B.; Phillips, Linda; Mustoe, Thomas A.; VanderZee, A. John; Wiersema, Laurel; Roach, Dell E.; Heggers, John P.; Hill, Donald P.; Taylor, Eugene L.; Robson, Martin C.

In: Journal of Vascular Surgery, Vol. 16, No. 2, 1992, p. 251-257.

Research output: Contribution to journalArticle

Bishop, JB, Phillips, L, Mustoe, TA, VanderZee, AJ, Wiersema, L, Roach, DE, Heggers, JP, Hill, DP, Taylor, EL & Robson, MC 1992, 'A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers', Journal of Vascular Surgery, vol. 16, no. 2, pp. 251-257. https://doi.org/10.1016/0741-5214(92)90115-O
Bishop, Jon B. ; Phillips, Linda ; Mustoe, Thomas A. ; VanderZee, A. John ; Wiersema, Laurel ; Roach, Dell E. ; Heggers, John P. ; Hill, Donald P. ; Taylor, Eugene L. ; Robson, Martin C. / A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. In: Journal of Vascular Surgery. 1992 ; Vol. 16, No. 2. pp. 251-257.
@article{5cd213f12dc74348b944714933215f98,
title = "A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers",
abstract = "Chronic wounds such as venous stasis ulcers have become a socioeconomic problem. Even with successful initial management, the recurrence rate approaches 70{\%}. With the advent of new wound healing agents, nonoperative attempts to heal these wounds appear indicated. This study reports a prospective randomized evaluator-blinded trial comparing two potential wound healing agents to an inert vehicle placebo. Eighty-six evaluable patients completed the trial. Silver sulfadiazine 1{\%} in a cream proved to statistically reduce the ulcer size compared with a biologically active tripeptide copper complex 0.4{\%} cream formulation or the placebo. There was no difference between the latter two treatments. Silver sulfadiazine has been shown to allow keratinocyte replication and to have antiinflammatory properties. In this trial its antibacterial action was not used since all ulcers had comparable bacterial levels (≤ 105/gm of tissue) before treatment. These results suggest that the silver sulfadiazine cream used in this study may facilitate healing in wounds healing largely by the process of epithelization.",
author = "Bishop, {Jon B.} and Linda Phillips and Mustoe, {Thomas A.} and VanderZee, {A. John} and Laurel Wiersema and Roach, {Dell E.} and Heggers, {John P.} and Hill, {Donald P.} and Taylor, {Eugene L.} and Robson, {Martin C.}",
year = "1992",
doi = "10.1016/0741-5214(92)90115-O",
language = "English (US)",
volume = "16",
pages = "251--257",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

AU - Bishop, Jon B.

AU - Phillips, Linda

AU - Mustoe, Thomas A.

AU - VanderZee, A. John

AU - Wiersema, Laurel

AU - Roach, Dell E.

AU - Heggers, John P.

AU - Hill, Donald P.

AU - Taylor, Eugene L.

AU - Robson, Martin C.

PY - 1992

Y1 - 1992

N2 - Chronic wounds such as venous stasis ulcers have become a socioeconomic problem. Even with successful initial management, the recurrence rate approaches 70%. With the advent of new wound healing agents, nonoperative attempts to heal these wounds appear indicated. This study reports a prospective randomized evaluator-blinded trial comparing two potential wound healing agents to an inert vehicle placebo. Eighty-six evaluable patients completed the trial. Silver sulfadiazine 1% in a cream proved to statistically reduce the ulcer size compared with a biologically active tripeptide copper complex 0.4% cream formulation or the placebo. There was no difference between the latter two treatments. Silver sulfadiazine has been shown to allow keratinocyte replication and to have antiinflammatory properties. In this trial its antibacterial action was not used since all ulcers had comparable bacterial levels (≤ 105/gm of tissue) before treatment. These results suggest that the silver sulfadiazine cream used in this study may facilitate healing in wounds healing largely by the process of epithelization.

AB - Chronic wounds such as venous stasis ulcers have become a socioeconomic problem. Even with successful initial management, the recurrence rate approaches 70%. With the advent of new wound healing agents, nonoperative attempts to heal these wounds appear indicated. This study reports a prospective randomized evaluator-blinded trial comparing two potential wound healing agents to an inert vehicle placebo. Eighty-six evaluable patients completed the trial. Silver sulfadiazine 1% in a cream proved to statistically reduce the ulcer size compared with a biologically active tripeptide copper complex 0.4% cream formulation or the placebo. There was no difference between the latter two treatments. Silver sulfadiazine has been shown to allow keratinocyte replication and to have antiinflammatory properties. In this trial its antibacterial action was not used since all ulcers had comparable bacterial levels (≤ 105/gm of tissue) before treatment. These results suggest that the silver sulfadiazine cream used in this study may facilitate healing in wounds healing largely by the process of epithelization.

UR - http://www.scopus.com/inward/record.url?scp=0026672429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026672429&partnerID=8YFLogxK

U2 - 10.1016/0741-5214(92)90115-O

DO - 10.1016/0741-5214(92)90115-O

M3 - Article

VL - 16

SP - 251

EP - 257

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 2

ER -